PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau
Interview with Christopher Moreau, CEO of Algernon Pharmaceuticals with host Cyndi Edwards of PRMediaNow regarding the announcement that Ifenprodil has reduced Interleukin 6 with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 study.